Two significant principles are needed for TTP to occur: firstly, antibodies against ADAMTS-13 that decrease its activity, and secondly, a trigger that induces systemic endothelial cell damage [3]. The gene discussed is ADAMTS13; the disease is thrombotic thrombocytopenic purpura.